Hsbc Holdings PLC Buys New Holdings in Ultragenyx Pharmaceutical Inc (RARE)

Share on StockTwits

Hsbc Holdings PLC bought a new stake in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 4,167 shares of the biopharmaceutical company’s stock, valued at approximately $213,000.

Several other large investors have also recently modified their holdings of the company. American Century Companies Inc. boosted its holdings in shares of Ultragenyx Pharmaceutical by 2.8% in the first quarter. American Century Companies Inc. now owns 36,720 shares of the biopharmaceutical company’s stock valued at $1,872,000 after acquiring an additional 997 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Ultragenyx Pharmaceutical by 5.0% during the first quarter. Wells Fargo & Company MN now owns 24,200 shares of the biopharmaceutical company’s stock worth $1,234,000 after buying an additional 1,149 shares in the last quarter. Verity Asset Management Inc. boosted its holdings in Ultragenyx Pharmaceutical by 26.4% during the first quarter. Verity Asset Management Inc. now owns 7,245 shares of the biopharmaceutical company’s stock worth $369,000 after buying an additional 1,512 shares in the last quarter. UBS Asset Management Americas Inc. boosted its holdings in Ultragenyx Pharmaceutical by 6.5% during the fourth quarter. UBS Asset Management Americas Inc. now owns 26,662 shares of the biopharmaceutical company’s stock worth $1,237,000 after buying an additional 1,636 shares in the last quarter. Finally, American International Group Inc. boosted its holdings in Ultragenyx Pharmaceutical by 6.8% during the first quarter. American International Group Inc. now owns 28,483 shares of the biopharmaceutical company’s stock worth $1,452,000 after buying an additional 1,820 shares in the last quarter. 96.03% of the stock is currently owned by institutional investors and hedge funds.

Shares of Ultragenyx Pharmaceutical opened at $84.26 on Friday, according to Marketbeat Ratings. The stock has a market cap of $4.25 billion, a price-to-earnings ratio of -11.23 and a beta of 1.97. Ultragenyx Pharmaceutical Inc has a 12-month low of $41.67 and a 12-month high of $86.10.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Monday, May 7th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.81. The business had revenue of $10.68 million for the quarter, compared to analyst estimates of $56.58 million. During the same quarter in the previous year, the firm posted ($1.63) EPS. equities analysts expect that Ultragenyx Pharmaceutical Inc will post -5.32 EPS for the current year.

A number of research firms recently commented on RARE. Robert W. Baird reissued a “buy” rating and set a $70.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, February 23rd. BidaskClub raised shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, April 14th. ValuEngine raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Wednesday, April 11th. Credit Suisse Group downgraded shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and boosted their price objective for the stock from $67.00 to $80.00 in a report on Thursday. They noted that the move was a valuation call. Finally, credit downgraded shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and boosted their price objective for the stock from $67.00 to $80.00 in a report on Thursday. One analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $71.26.

In other news, VP Theodore Alan Huizenga sold 1,338 shares of the business’s stock in a transaction that occurred on Wednesday, June 13th. The shares were sold at an average price of $76.97, for a total value of $102,985.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Shalini Sharp sold 13,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 30th. The shares were sold at an average price of $70.17, for a total transaction of $912,210.00. Following the completion of the transaction, the chief financial officer now directly owns 70,174 shares of the company’s stock, valued at approximately $4,924,109.58. The disclosure for this sale can be found here. In the last three months, insiders sold 31,003 shares of company stock valued at $2,275,942. Company insiders own 8.40% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply